The second pilar of the modern treatment of metastatic NSCLC is taken by immunotherapy (PD-1 and PD-L1 monoclonal antibodies), which is nowadays in the frontline of treatment in oncogenic driver–negative NSCLC and has produced response and survival rates that were unreachable a few years ago (18, 19). This evidence concerns the gene CD274 and non-small cell lung carcinoma.